Inclinix, a US-based contract research organisation (CRO) that provides customised solutions for patient enrolment into Phase I-IV clinical trials, has merged with PMG Research, which runs an Integrated Site Network of clinical research facilities in the southeast region of the United States.

No financial details were released on the deal, which the new partners said creates “a first-of-kind organisation for accelerating clinical trial enrolment from beginning to end”. The transaction was funded by a consortium of investors led by private equity firm Frontier Capital.

Based (like Inclinix and PMG) in North Carolina, US, Frontier Capital boosted the former’s coffers in January 2008 when it made a US$10 million investment in Inclinix to support further enhancements to the company’s proprietary patient-enrolment processes and technologies, as well as additional sales, marketing and service-delivery resources and corporate facilities.

The new company, Inclinix-PMG Holdings, will operate in the short term as two divisions. It will be led by J. Tobin Geatz as president and chief executive officer – positions he previously held at Ingenix – and by  Jeffrey Reiniche, former chief financial officer at Ingenix and now CFO of the combined businesses. 

Bundling the basics 

 “This novel business combination will allow sponsors and CROs to bundle the two most important services in a trial: world-class sites and patient recruiting,” Geatz commented. 

“We will have more than 120 Principal Investigators and 80 study co-ordinators, who together with Inclinix's 75+ global Clinical Enrollment Managers provide our customers [with] rapid enrolment locally and worldwide.”

Founded in 1999, Inclinix was known as PharmaTech Solutions until June 2006, when it changed its name following a merger with Realinterface Expert Systems of Annapolis, Maryland, integrating PTS’ recruitment services and RESI’s patient screening technology platform (which included the clinical trial recruiting and management application InClinix).

The Inclinix service offering includes enrolment feasibility, investigator recruitment, site support, and patient recruitment, retention and monitoring through the company’s enrolment clinical-research associates.